ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

HVO Hvivo Plc

29.50
0.60 (2.08%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hvivo Plc LSE:HVO London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.60 2.08% 29.50 28.50 29.50 29.00 28.90 28.90 746,449 16:35:09
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 48.48M -776k -0.0011 -263.64 195.77M

hVIVO plc Directors' Dealings (2819M)

12/10/2016 7:00am

UK Regulatory


Hvivo (LSE:HVO)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Hvivo Charts.

TIDMHVO

RNS Number : 2819M

hVIVO plc

12 October 2016

For immediate release 7.00am: 12 October 2016

HVIVO PLC

("hVIVO" or the "Company")

Directors' Dealings

hVIVO plc (AIM: HVO), a specialty biopharma company with clinical testing capabilities, announces that application has been made to AIM for the admission of 10,767 new ordinary shares of 5.0p each in the Company (the "New Ordinary Shares").

The New Ordinary Shares have been allotted pursuant to the purchase by Jaime Ellertson (Non-Executive Chairman) and Jim Winschel (Non-Executive Director) of new ordinary shares, under the terms of their letters of appointment as set out in the Company's announcement of 4 November 2014 which stated that Mr Ellertson and Mr Winschel had entered into binding commitments to purchase $20,000 and GBP4,000 of hVIVO plc new ordinary shares respectively per quarter. The New Ordinary Shares represent their investments for the quarter ended 30 September 2016. On 11 October 2016, Mr Ellertson invested in an additional 8,546 ordinary shares and Mr Winschel invested in an additional 2,221 ordinary shares, at a price of 180.1 pence per share.

Following admission of the New Ordinary Shares to trading on AIM, the total number of ordinary shares with voting rights in issue will be 78,101,077 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Admission of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, is expected to occur on 17 October 2016. Following Admission, Mr Ellertson and Mr Winschel will be interested in a total of 55,040 and 34,706 ordinary shares of 5.0p in the Company respectively, each representing less than 0.1% of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the persons discharging managerial responsibilities/persons 
       closely associated 
---  ------------------------------------------------------------------------- 
 a)   Name                       Jaime Ellertson and Jim Winschel 
---  -------------------------  ---------------------------------------------- 
 2    Reason for the notification 
---  ------------------------------------------------------------------------- 
 a)   Position/                  Non-Executive Chairman and Non-Executive 
       status                     Director 
---  -------------------------  ---------------------------------------------- 
 b)   Initial notification/      Initial Notification 
       Amendment 
---  -------------------------  ---------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
---  ------------------------------------------------------------------------- 
 a)   Name                       hVIVO plc 
---  -------------------------  ---------------------------------------------- 
 b)   Legal Entity               N/A 
       Identifier 
---  -------------------------  ---------------------------------------------- 
 4    Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
---  ------------------------------------------------------------------------- 
 a)   Description                Ordinary shares of 5 pence each 
       of the financial 
       instrument, 
       type of instrument         GB00B6ZM0X53 
 
       Identification 
       code 
---  -------------------------  ---------------------------------------------- 
 b)   Nature of                  Acquisition of ordinary shares 
       the transaction 
---  -------------------------  ---------------------------------------------- 
 c)   Currency                   GBP 
---  -------------------------  ---------------------------------------------- 
 d)   Price(s) and                   Director           Price (p)   Volume 
       volume(s)                     -----------------  ----------  ------- 
                                      Jaime Ellertson    180.1       8,546 
                                     -----------------  ----------  ------- 
                                      Jim Winschel       180.1       2,221 
                                     -----------------  ----------  ------- 
---  ------------------------- 
 
 e)   Aggregated 
       information 
       - Aggregated 
        volume 
       - Price                    10,767 
       - Aggregated                180.1p 
        total 
                                   GBP19,391.37 
---  -------------------------  ---------------------------------------------- 
 f)   Date of the                11 October 2016 
       transaction 
---  -------------------------  ---------------------------------------------- 
 g)   Place of the               London Stock Exchange, AIM 
       transaction 
---  -------------------------  ---------------------------------------------- 
 

For further information please contact:

hVIVO plc +44 207 756 1300

Kym Denny (Chief Executive Officer)

Graham Yeatman (Chief Financial & Business Officer)

Media Enquiries +44 203 021 3933 / +44 7854 979 420

Colin Paterson (Director of Marketing, Communication and Public Relations)

Numis Securities Limited +44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Michael Burke (Corporate Broking)

Notes to Editors:

hVIVO plc ("hVIVO"), a specialty biopharma company with clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 45 clinical studies, inoculated over 2000 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHGGGWGUUPQPUG

(END) Dow Jones Newswires

October 12, 2016 02:00 ET (06:00 GMT)

1 Year Hvivo Chart

1 Year Hvivo Chart

1 Month Hvivo Chart

1 Month Hvivo Chart

Your Recent History

Delayed Upgrade Clock